Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)

Michael Böhm, Ana Cristina Perez, Pardeep S. Jhund, Jan C. Reil, Michel Komajda, Michael R. Zile, Robert S. McKelvie, Inder Anand, Barry M. Massie, Peter E. Carson, John J.V. McMurray

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Background Higher heart rate is associated with poorer outcomes in patients with heart failure and reduced ejection fraction (HF-REF). Less is known about the association between heart rate and outcomes in patients with heart failure and preserved ejection fraction (HF-PEF). Therefore, we examined the relationship between heart rate and outcomes in the irbesartan in patients with heart failure and preserved systolic function trial (I-Preserve) in patients with an ejection fraction >45% aged >60 years. Methods and results Heart rate was analysed as both a categorical (tertiles) and continuous variable. Patients in sinus rhythm (n = 3271) and atrial fibrillation (n = 696) were analysed separately. The outcomes examined were the primary endpoint of the trial (all-cause death or cardiovascular hospitalization), the composite of cardiovascular death or heart failure hospitalization (and its components) and all-cause death alone. Higher heart rate was associated with a significantly higher risk of all outcomes studied for patients in sinus rhythm, even after adjustment for other prognostic variables, including N-terminal pro-B-type natriuretic peptide. Each standard deviation (12.4 bpm) increase in heart rate was associated with an increase in risk of 13% for cardiovascular death or heart failure hospitalization (P = 0.002). No relationship between heart rate and outcomes was observed for patients in atrial fibrillation. Beta-blocker treatment did not reduce the heart rate-risk relationship. Conclusions In patients with heart failure and preserved ejection fraction, heart rate is in sinus rhythm an independent predictor of adverse clinical outcomes and might be a therapeutic target in this syndrome. Clinical Trial Registration - URL http://www.clinicaltrials.gov. Unique identifier: NCT 0095238

Original languageEnglish (US)
Pages (from-to)778-787
Number of pages10
JournalEuropean Journal of Heart Failure
Volume16
Issue number7
DOIs
StatePublished - Jul 2014

Keywords

  • Heart failure
  • Heart rate
  • Irbesartan
  • Morbidity
  • Mortality

Fingerprint Dive into the research topics of 'Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)'. Together they form a unique fingerprint.

Cite this